At the cutting edge of biotechnology
iX Biopharma focuses on the development and commercialisation of novel wafer formulations to improve the quality of life of those suffering from pain and other health conditions
SINCE joining Singapore Exchange (SGX)-listed specialty pharmaceutical company iX Biopharma, Janakan Krishnarajah has been getting involved in many new aspects of the drug making business.
Dr Krishnarajah, a specialist in the fields of clinical pharmacology and internal medicine, had previously held the position of CEO and medical director at Linear Clinical Research - an Australian clinical trials facility.
There, the 42-year-old developed extensive experience in Phases I-IV clinical trials. He acted as principal or co-investigator in more than a hundred Phase I-II clinical trials.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Porsche posts Q1 profit drop on ramp-up costs
IBM plots US$730 million expansion of Canadian semiconductor site
Seatrium unit to fully redeem S$500 million worth of floating-rate bonds early
Yeo Guat Kwang, John Chen retiring from corporate boards
US: Wall St opens higher
Air China orders homegrown C919s in challenge to jet duopoly